Empagliflozin's role in reducing ventricular repolarization heterogeneity: insights into cardiovascular mortality decline from the EMPATHY-HEART trial

Back

ESC Professional Premium Access

Empagliflozin's role in reducing ventricular repolarization heterogeneity: insights into cardiovascular mortality decline from the EMPATHY-HEART trial

Session: Metabolic syndrome and heart disease (2)

Topic: Pharmacotherapy

Speaker: Doctor C. Lauretti (Sao Paulo, BR)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Doctor Cristiane Lauretti

University of Sao Paulo, Sao Paulo (Brazil)

0 follower

4 more presentations in this session

HFpEF and glycemic variability: GHIDD Trial

Speaker: Professor G. Fazio (Palermo, IT)

Telomere length across spectrum of metabolic health.

Speaker: Associate Professor T. Osadnik (Zabrze, PL)

Spermidine attenuates left ventricular dysfunction in estrogen deprived aging rats through mitigating lipid peroxidation and mitochondrial dysfunction

Speaker: Doctor C. Maneechote (Chiang Mai, TH)

Elevated levels of plasma inactive stromal cell derived factor-1a predict long-term adverse outcomes in diabetic patients with coronary artery disease

Speaker: Assistant Professor Y. Chikata (Tokyo, JP)

Access the full session

Metabolic syndrome and heart disease (2)

Speakers: Doctor C. Lauretti, Professor G. Fazio, Associate Professor T. Osadnik, Doctor C. Maneechote, Assistant Professor Y. Chikata

Access

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources